Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Morris

Showing results (161-170 of 324) with videos related to

Pageof 33
Sort By:
AIDS Research and Human Retroviruses|June 25, 2002
HIV-1 Subtype A, D, G, AG and unclassified sequences identified in South AfricaHelba Bredell, Gillian Hunt, Alison Casteling, et al.
Journal of Virology|August 21, 2009
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external regionElin S Gray, Maphuti C Madiga, Penny L Moore, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|April 16, 2013
Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveysEmmi Andersson, Wei Shao, Irene Bontell, et al.
Journal of Virology|July 30, 2005
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesJohn R Mascola, Patricia D'Souza, Peter Gilbert, et al.
Journal of Virology|March 2, 2012
UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype CHazel T Mufhandu, Elin S Gray, Maphuti C Madiga, et al.
The Lancet. Infectious Diseases|June 6, 2015
Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysisHelen Payne, Nonhlanhla Mkhize, Kennedy Otwombe, et al.
AIDS (London, England)|March 17, 2009
Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistanceNeil A Martinson, Lynn Morris, Jeffrey Johnson, et al.
The Lancet. Infectious Diseases|March 20, 2012
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trialLouise Kuhn, Ashraf Coovadia, Renate Strehlau, et al.
AIDS (London, England)|May 3, 2014
Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxisLouise Kuhn, Gillian Hunt, Karl-Günter Technau, et al.
BMC Infectious Diseases|September 19, 2019
Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4-8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011-12 and 2012-13Gillian M Hunt, Johanna Ledwaba, Anna Salimo, et al.
Pageof 33

Showing results (161-170 of 324) with videos related to

Sort By:
Pageof 33
AIDS Research and Human Retroviruses|June 25, 2002
HIV-1 Subtype A, D, G, AG and unclassified sequences identified in South AfricaHelba Bredell, Gillian Hunt, Alison Casteling, et al.
Journal of Virology|August 21, 2009
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external regionElin S Gray, Maphuti C Madiga, Penny L Moore, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|April 16, 2013
Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveysEmmi Andersson, Wei Shao, Irene Bontell, et al.
Journal of Virology|July 30, 2005
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesJohn R Mascola, Patricia D'Souza, Peter Gilbert, et al.
Journal of Virology|March 2, 2012
UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype CHazel T Mufhandu, Elin S Gray, Maphuti C Madiga, et al.
The Lancet. Infectious Diseases|June 6, 2015
Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysisHelen Payne, Nonhlanhla Mkhize, Kennedy Otwombe, et al.
AIDS (London, England)|March 17, 2009
Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistanceNeil A Martinson, Lynn Morris, Jeffrey Johnson, et al.
The Lancet. Infectious Diseases|March 20, 2012
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trialLouise Kuhn, Ashraf Coovadia, Renate Strehlau, et al.
AIDS (London, England)|May 3, 2014
Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxisLouise Kuhn, Gillian Hunt, Karl-Günter Technau, et al.
BMC Infectious Diseases|September 19, 2019
Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4-8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011-12 and 2012-13Gillian M Hunt, Johanna Ledwaba, Anna Salimo, et al.
Pageof 33